[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368363-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-368363-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","metachronous-gastro-oesophageal-adenocarcinoma-in-a-patient-with-colon-adenocarcinoma","Metachronous gastro-oesophageal adenocarcinoma in a patient with colon adenocarcinoma","","Case report describing a woman in her 70s who initially declined colon cancer screening and was later diagnosed with colon adenocarcinoma after melena and anaemia. After right hemicolectomy and chemotherapy for stage IIIc disease, about one year later she developed hepatic metastasis and a gastro-oesophageal mass confirmed as gastro-oesophageal adenocarcinoma. The report reviews the clinical challenge of metachronous malignancies in colorectal cancer survivors, highlighting surveillance limitations and the need to consider earlier detection strategies for high-risk patients.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/metachronous-gastro-oesophageal-adenocarcinoma-in-a-patient-with-colon-adenocarcinoma/368363/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/metachronous-gastro-oesophageal-adenocarcinoma-in-a-patient-with-colon-adenocarcinoma/368363.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-09","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":26},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What led to the initial diagnosis of colon cancer in this case?","Question",{"text":62,"@type":63},"Melena and anaemia with iron deficiency prompted evaluation, and subsequent work-up led to diagnosis of colon adenocarcinoma.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"When was the metachronous gastro-oesophageal cancer detected?",{"text":67,"@type":63},"Approximately one year after right hemicolectomy and chemotherapy for stage IIIc colon cancer, the patient was found to have hepatic metastasis and a gastro-oesophageal mass confirmed as adenocarcinoma.",{"name":69,"@type":60,"acceptedAnswer":70},"Why do current CRC survivor surveillance guidelines have limitations?",{"text":71,"@type":63},"The case background notes that while colonoscopy-based recommendations support earlier detection of metachronous colorectal cancers, cancers developing in other GI sites (stomach and oesophagus) reveal gaps in existing surveillance guidance.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},368363,1790176530,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":26,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":33,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":79,"read_time":123,"preview_page_count":33,"preview_urls":143},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Case report  \nMetachronous gastro-oesophageal adenocarcinoma in a patient with colon adenocarcinoma  \nMarcelle Meseeha  , 1 Sanyukta Dudhat  ,2 Laraib Sehrish  ,2 Maximos Attia  2  \n1Hematology/Oncology, Guthrie Medical Group PC, Sayre, Pennsylvania, USA  \n2Family Medicine, Guthrie Medical Group PC, Sayre, Pennsylvania, USA  \nCorrespondence to  \nDr Maximos Attia;  \n[maximos.attia@guthrie.org](maximos.attia@guthrie.org)  \nAccepted 20 March 2025  \n© BMJ Publishing Group Limited 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nTo cite: Meseeha M, Dudhat S, Sehrish L, et al. BMJ Case Rep 2025;18:e264826 . doi:10 . 1136/bcr-2025- 264826  \nSUMMARY  \nA woman in her 70s, who previously declined  \ncolon cancer screening, was diagnosed with colon adenocarcinoma after she presented with melena and anaemia. After she underwent right hemicolectomy and chemotherapy for stage IIIc colon cancer, approximately 1 year later, she was found to have hepatic metastasis and a gastro-oesophageal mass confirmed as gastrooesophageal adenocarcinoma. This case report shedslight on the challenge that patients and clinicians face in cases of metachronous cancers developing in colorectal cancer survivors, and it raises the consideration for possible improvement of the screening guidelines to help detect metachronous cancers earlier in high-risk patients, hence potentially improving the long-term outcomes for these patients.  \nBACKGROUND  \nMetachronous cancers in colorectal cancer (CRC) survivors pose a significant clinical challenge. Although CRC survivors have increasing survival rates secondary to the advances in early detection and treatment, they still have a high risk of developing another primary cancer several months after the first cancer either in the colon or in another gastrointestinal site. This situation makes it necessary to look into strategies that would provide better surveillance for these patients. The US Multi-Society Task Force on Colorectal Cancer and the American Gastroenterological Association provided recommendations regarding surveillance via colonoscopy for CRC survivors. That led to early detection of metachronous colorectal cancersand subsequently higher survival rates among these patients, as these cancers are usually asymptomatic, especially in early stages, complicating timely detection if there is no systematic follow-up. Metachronous cancers that may happen in other sites of the gastrointestinal (GI) tract, namely, the stomach and oesophagus, highlight some limitations in the current guidelines addressing metachronous CRC patient surveillance.1  \nBeyond colonoscopic findings of adenomas in CRC survivors, there are other factors that significantly increase the risk of developing subsequent cancers. For example, deficiencies in mismatch repair (MMR) genes, as in cases of Lynch syndrome, are linked to an increased risk of metachronous cancers.2 These genetic predispositions, as in the case of Lynch syndrome, significantly increase the risk of multiple primary malignancies including cancers of the gastrointestinal tract, among other organs.3  \nThis group of patients would probably benefit from more intensive surveillance protocols tailored for them. Continued research in this regard is essential. By integrating this genetic counselling and tailored surveillance, clinicians can better manage the high risks associated with these conditions of MMR gene deficiencies and Lynch syndrome, ultimately improving patient outcomes. While guidelines for gastro-oesophageal cancer surveillance in CRC survivors are less clearly defined, emerging evidence suggests that upper gastrointestinal endoscopy maybe beneficial in high-risk patients. Risk factors such as a personal or family history of upper gastrointestinal cancers, Barrett’s oesophagus, or other predisposing conditions should prompt clinicians to consider adding endoscopic surveillance to their follow-up care.4 5 In regi","cbCairrUyAzk3bAu","https://ap.wps.com/l/cbCairrUyAzk3bAu","pdf",599515,"English","# Summary\n# Background\n# Case presentation","[{\"question\":\"What led to the initial diagnosis of colon cancer in this case?\",\"answer\":\"Melena and anaemia with iron deficiency prompted evaluation, and subsequent work-up led to diagnosis of colon adenocarcinoma.\"},{\"question\":\"When was the metachronous gastro-oesophageal cancer detected?\",\"answer\":\"Approximately one year after right hemicolectomy and chemotherapy for stage IIIc colon cancer, the patient was found to have hepatic metastasis and a gastro-oesophageal mass confirmed as adenocarcinoma.\"},{\"question\":\"Why do current CRC survivor surveillance guidelines have limitations?\",\"answer\":\"The case background notes that while colonoscopy-based recommendations support earlier detection of metachronous colorectal cancers, cancers developing in other GI sites (stomach and oesophagus) reveal gaps in existing surveillance guidance.\"}]","Metachronous gastro-oesophageal adenocarcinoma in a patient with colon adenocarcinoma | PDF",[144,148,152,156],{"page_no":22,"url":145,"width":146,"height":147},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f8beaa03648899a8e2d5f0eb485d886d.webp",983,1310,{"page_no":26,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69b0360cc3ff51d5d0bcb1ccf04ea4d8.webp",982,1309,{"page_no":30,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e63d9c90eb800c2003893f854008470.webp",981,1308,{"page_no":33,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9993e434b047992365930e06a9e0dc75.webp",980,1306]